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Bone is a form of mineralized connective tissue that provides strength and rigidity 
to the skeleton 1, 10. The two primary components within bone tissue are an organic 
extracellular matrix, containing type I collagen, and an inorganic mineral component 
composed mainly of calcium phosphate hydroxyapatite crystals 1, 22, 32. Over time the 
microarchitecture of bone can break down due to a variety of different factors, mainly the 
onset of osteoporosis in post-menopausal women, Paget’s disease, and the experience of 
a loss of gravity during space flight. Currently there are about ten million people in the 
United States alone suffering from osteoporosis 10.  
The prevention of further damage as well as the replacement of lost bone tissue is 
the focus of many therapeutic approaches. A large number of available treatments rely on 
the concept of blocking further bone loss by inhibiting the natural resorption process. 
Bisphosphonates are the most popular drug therapy in this category 43. But there are 
many other treatments that strive to prevent further bone resorption such as hormone 
therapy, estrogen agonist / antagonists, calcitonin, and denosumab. Other therapies 
approach the problem of bone loss by inducing the formation of new bone tissue to 
replace that lost to these pathologies. These include teriparatide, strontium ranelate, and 
statins, which are the focus of this research.  
The goal of this research was to formulate a targeted nanoparticle drug delivery 
system for the treatment of bone diseases. A hydroxyapatite nanoparticle conjugated with 
poly(glycolic acid)-poly(ethylene glycol) diblock copolymer was created to deliver statin 
drugs. These drugs act as competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme 
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A reductase, for the lowering of serum cholesterol 12, 49. Recently, statins have been 
investigated for their ability to induce bone formation by enhancing expression of bone 
morphogenic protein-2 12, 49.  
In addition to formulation, studies were completed to prove the particle’s low 
toxicity, loading abilities, and release pharmacokinetics. In order to enhance the 
specificity with which these particles are delivered to bone, targeting peptides were tested 
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 The research presented in this thesis focuses on the treatment of bone diseases 
such as osteoporosis, Paget’s disease, and microgravity bone loss. All of these 
pathologies are similar in that they result from a dysfunction or uncoupling of bone’s 
natural resorption and formation processes. These diseases of bone can result in traumatic 
fracture, deformity, and pain 10, 23.  
 An overview is provided outlining the normal anatomy of bone tissue, including 
the microstructure, macrostructure, cellular components, and the remodeling process. 
Following the anatomical overview each disease, osteoporosis, Paget’s, and microgravity 
bone loss, is detailed. Though each disease has different causes and physiological 
changes, they all results in a decreased bone density as well as an increased risk of 
fracture. 
 A literature review was preformed to provide information on the all the currently 
marketed and researched treatment options. These treatments fall into one of two 
categories. Anti-catabolic treatments focus on the cessation of the resorption process and 
the retention of current bone mass and structure. While anabolic therapies act to induce 
bone formation to replace lost bone mass. Many different treatment options are detailed 
with in vitro, in vivo, and clinical findings, as well as the currently researched delivery 
options. 
 The focus of this research was an anabolic treatment option of using statins, a 
commonly prescribed cholesterol-lowering drug, for the induction of bone formation. The 
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goal was to deliver these drugs with a biocompatible, targeted nanoparticle delivery 
system. Hydroxyapatite nanoparticles were made with a polymeric coating for increased 
compatibility and circulation time. These particles were shown to encapsulate and release 
drug with a linear release profile. Targeting options were also investigated to ensure these 
particles were delivered exclusively to the bone. 
 This paper provides both an overview of current research was well as a detailed 








Bone is a complex living form of specialized connective tissue that serves many 
vital functions in the body. The mineralized extracellular matrix, ECM, gives bone its 
rigidity such that it can provide mechanical support, protection of vital organs, mobility, 
as well as act as a reservoir for vital minerals 1, 10, 27, 30. Due to bone’s multi-functionality, 
healthy bone tissue is critically important to overall health and quality of life 10.  
 
2.1.1. Bone Microstructure 
Bone tissue consists primarily of two different components, an organic portion, 
mainly cells and the ECM. Also an inorganic, or mineral, component comprised of 
calcium phosphate in the form of hydroxyapatite rod shaped nano-crystals twenty-five to 
fifty nanometers in length 1, 22, 32. Collagen is the main protein providing structural 
integrity to the ECM; this network of triple helical collagen molecules encompasses 
ninety percent of the total bone mass 1, 24, 30, 32. The ECM is impregnated with the mineral 
component, thus providing rigidity to the tissue 1, 32. These hydroxyapatite crystals, 
Ca10(PO4)6(OH)2, not only give bone its hardness, but it also allows for the tissue to be 
used as a storehouse for both calcium and phosphate. In order to maintain homeostatic 
blood calcium and phosphate levels, the bone can be broken down such that these 
minerals can be utilized elsewhere in the body 1, 10, 30. In addition to collagen and 
hydroxyapatite, the bone matrix contains proteoglycan molecules. These molecules 
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consist of a core protein with covalently bound glycosaminoglycan (GAG) side chains. 
These proteoglycans allow for the binding of growth factors as well as lend to the tissue’s 
compressive strength 1, 30. Other common molecules found in the bone ECM are 
glycoproteins that mediate attachment between various components of the matrix 1, 30.  
 
2.1.2. Bone Macrostructure 
Bone tissue, both microscopically and macroscopically, is structured such that it 
provides maximum strength in order to prevent fracture. In bulk, bone contains two 
distinct layers. The outer layer, made of dense highly organized structures, is known as 
compact, or cortical bone. Cortical bone has cylindrical structures known as osteons 
containing concentric rings of bone tissue, each layer have a different collagen fiber 
orientation 1, 32. Osteocytes reside in small spaces within the concentric rings of bone 
matrix called lacunae. Extending out from these voids are small tunnels known as 
canaliculi, these tunnels act as pathways through which extensions of osteocytes can 
travel and connect to neighboring cells 1, 32. The second, inner layer bone tissue is 
trabecular or cancellous bone. This type of tissue is much less dense and forms a network 
of small struts, called trabeculae, of bone tissue extending in various directions with a 
continuous interstitial space. Between the concentric arrangement within the cortical 
bone and the random arrangement of struts allowing for even stress distribution, bone 
tissue is specially formed to provide extensive structure and strength to the body 23. A 
layer of dense connective tissue surrounds the bone, both superficially and deep, to allow 
for cellular attachment during remodeling and enhanced vascularization. The superficial 
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layer is known as the periosteum, this layer of dense connective tissue resides on the 
outer surface of the cortical bone 1. The internal surface of the bone is surrounded by a 
single cell layer of osteoprogenitor cells, which can become active in times of 
remodeling. This endosteum internally surrounds the layer of cortical bone as well as 
wraps around each trabeculae. This tissue layer remains stagnant until times of 
remodeling when it thickens, allowing a layer of cells to reside and attach to the bone 
surface 1.  
Bone is a highly vascularized tissue containing an interconnected network of 
vessels. This vascular network consists of many different vessels and structures including 
the medullary cavity, nutrient foramina, Haversian canals and Volkmann’s canals. Within 
the center of long bones is a cavity known as the medullary cavity, in which bone 
marrow, consisting of developing blood cells and reticular fiber, resides 1, 39. The main 
route by which blood enters the bone tissue is by multiple nutrient foramina, small 
openings in the bone through which blood vessels pass 1. These incoming vessels supply 
blood to the medullary cavity, where the network of vessels within the tissue originates 1. 
From the medullary cavity, Volkmann’s canals provide a route of entry into the compact 
bone. These canals run perpendicular to the axial length of the bone. Originating from 
these Volkmann’s canals are Haversian canals that run through the center of each 
individual osteon. Within these Volkmann’s and Haversian canals are capillaries that 
allow for the diffusion of nutrients to bone cells due to the ease of movement across the 
single cellular endothelial layer of the capillaries 1, 38, 39. Haversian canals are typically 
200-300 nanometers apart; this distance is such that each bone cell is close enough to 
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receive nutrients by diffusion 38, 39. Trabecular bone is also vascularized by a similar 
network of capillaries that runs between the trabecular struts within the bone marrow 39. 
The cells within cancellous bone are provided nutrients from these vessels running 
through the interstices of the tissue 39. The fenestrations, or pores, within bone 
vasculature, facilitate this diffusion of nutrients; these openings can be up to eighty 
nanometers, large enough for delivery of nutrients and therapeutic treatments 98. 
 
 
2.1.3. Cellular Components 
The cellular component of bone tissue is comprised of five different cell types. 
Osteoblasts are anabolic bone cells, playing a role in new bone formation. They are 
mononuclear cells that function to synthesize and secrete collagen, GAGs, and other bone 
Figure 1 | Anatomy of Native Bone Tissue. Bone contains two concentric layers of 
mineralized tissue. Compact bone, with cylindrical osteons and Haverisan canals, 
reside on the periphery of the bone. Trabecular bone remains inferior with blood 
vessels and marrow vessels running within the trabecular struts. 
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matrix proteins.  This newly synthesized matrix, often called osteoid, will eventually be 
mineralized and thus new bone tissue is formed 1, 27, 29. These cells work in a coordinated 
manner to secrete sequential sheets of new osteoid 29. Once bone matrix secretion is 
complete, osteoblasts follow one of three paths. Some osteoblasts become flattened and 
remain on the periphery of the bone within the connective tissue periosteum and become 
bone-lining cells. Approximately ten percent of osteoblasts become embedded in the 
newly synthesized bone matrix and become osteocytes, and the remaining cells die by 
apoptosis 27. The bone-lining cells remain quiescent during times of no growth, and act to 
mediate biological signals and regulate bone resorption 1, 29. Osteocytes remain buried in 
small voids, known as lacunae, within the concentric layers of bone tissue that form 
osteons and function in osteocytic osteolysis, breaking down mineralized bone tissue, 
bone formation, and the transmission and response to mechanical stimuli 1, 29. Bone tissue 
also contains catabolic cells, known as osteoclasts, which act to break down mineralized 
bone. Osteoclasts attach to areas of bone, mainly the surface of the cortical bone or 
trabecular struts, at which point the cells dissolve the mineral components and hydrolyze 
the organic matrix 1, 27 31. Osteoclasts are often an area of research in treating 
osteoporosis. The main two osteoclastic molecules researched are a ligand known as 
RANKL and macrophage colony stimulating factor (M-CSF) 78, 79. These are membrane 
bound molecules on the surface of osteoclast precursors 78, 79. The last type of bone cell is 
an osteoprogenitor cell; a derivative of a mesenchymal stem cell that eventually gives rise 
to an osteoblast 1. 
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2.1.4. Remodeling Process 
Bone is a living tissue that is constant changing and remodeling in order to 
maintain mechanical competence and support body mass 27.  The skeleton is constantly 
adapting to the external loading and unloading seen throughout life. This adaptation 
manifests in changes to the bone architecture and mass in response to exercise, 
immobilization, or weightlessness 27, 31. These changes in the bone are mainly governed 
by a group of biological molecules, mainly, systemic hormones such as calcitonin, 
parathyroid hormone (PTH), and glucocorticoids as well as local factors like cytokines 
and growth factors 27. An increase in stress on the bone increases the rate of bone 
formation while reducing that of bone resorption, resulting in an increase in bone mass 27. 
The body creates the physiological response to increase bone mass in order to support the 
increased load as well as prevent fracture 27. This process also occurs in reverse, with a 
decrease in activity bone formation will slow or cease and the bone will begin to resorb 
since the high bone mass is no longer needed. When bone loss occurs due to a lack of 
mechanical stimulation it leads to a reduction in density, changes in spatial orientation as 
well as connectivity of trabecular struts. All of these changes decrease bone strength and 
increase the risk of fracture 27.  
Even when bone does not experience changing load levels, it is still constantly 
being remodeled without any change in mass or density. In fact, in a mature adult 
approximately twenty-five percent of trabecular and three percent of cortical bone is 
renewed annually 31. There are five main phases of bone remodeling: activation, 
resorption, reversal, formation, and quiescence. Activation is the initial event in which 
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the bone surface is converted from a quiescent state to one in which mononuclear cells 
are circulating to eventually fuse and form osteoclasts. The specific events that initiate 
this phase of bone remodeling are unknown 31.  The resorption phase begins and 
osteoclasts dissolve the mineral bone components and hydrolyze the organic matrix. This 
portion of the bone resorption process lasts forty-two days in cancellous bone and 
twenty-seven days in cortical bone 31. After osteoclasts have broken down the bone 
tissue, the reversal phase begins and allows transition time between resorption and 
formation. This stage lasts nine days in cancellous bone and four days in cortical bone, 
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Figure 2 | Diagram of Active Phase of Bone Remodeling. Displays the progression of 
bone remodeling from the activation of osteoclasts and the removal of bone tissue to the 
recruitment of osteoblasts to the previously resorbed site to lay down new bone tissue 10. 
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transition is complete, the formation period begins. Osteoblasts differentiate and lay 
down new unmineralized osteoid. After twenty-five or thirty-five days in trabecular and 
cortical bone respectively, the osteoid begins to mineralize. Once the remodeling is 
complete, bone returns to a stable quiescent state characterized by only a thin layer of 
lining cells surrounding the bone 31. Overall, the control and regulation of remodeling is 
done by the balance and coupling of osteoblast and osteoclast cells. It is this balance that 




Most bone diseases are characterized by bone loss due to an imbalance between 
the bone resorption and formation processes 29. The three main causes of decreased bone 
mass are osteoporosis, Paget’s disease, and microgravity bone loss. All three have 
different causes but a similar outcome, a decreased bone mineral density and increased 
risk of bone fracture 23, 27, 31.  
 
2.2.1. Osteoporosis 
Osteoporosis is a disease characterized by low bone mass and deterioration of 
bone structure that causes bone fragility and leads to an increased risk of fracture. The 
World Health Organization has defined osteoporosis as a bone mineral density (BMD) 
value more than 2.5 standard deviations below the mean for a normal young Caucasian 
woman 10. The severity of the disease is determined by a rating system developed by the 
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World Health Organization, called a T score. Below is a table defining the scoring system 
43. Currently, there are roughly ten million Americans over the age of fifty with 
osteoporosis, and another thirty-four million at risk of developing the disease 10. 
  
Osteoporosis is the most common bone disease, and is the most important 
underlying cause of fractures in the elderly 10. Though very few people die from this 
disease, an estimated 1.5 million individuals suffer from an osteoporotic fracture each 
year 10. In fact, forty percent of all white women, and thirteen percent of white men, over 
fifty years of age will experience a fracture of the hip, spine, or wrist within the 
remainder of their lifetime 10. This disease can affect anyone, but it is two to three times 
more likely to develop in women, partially due to the increased rate of bone loss at the 
onset of menopause 10. Women accounted for over seventy-five percent of all cases of 
osteoporosis of the hip in 2002 10. Aside from injuries and pain, osteoporosis is also a 
drain on the healthcare system. It has been estimated that the direct healthcare 
expenditures for osteoporotic fractures range from twelve to eighteen billion dollars per 
T Score Diagnosis 
0 to -0.99 Normal 
-1 to -2.499 Osteopenia 
≤ -2.5 Osteoporosis 
≤ -2.5 accompanied by fracture or history of 
fracture 
Severe osteoporosis 
Table 1 | World Health Organization Osteoporosis Scoring. T scores are used by 
physicians to determine the severity of the osteoporosis was well as the risk of future 
fracture 43. 
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year. The addition of indirect costs, such as caregivers and lost productivity, is thought to 
increase the figure by billions 10.  
 
Primary osteoporosis is a result of the cumulative bone loss and deterioration that 
occurs throughout life 10. This steady bone loss leads to compromised bone strength, 
predisposing the bone to an increased risk of fracture 10. During childhood bone mass 
increases linearly, reaching a peak in both males and females around twenty or thirty 
years of age.  At this time the trabecular layer within the bone begins to slowly thin, 
resulting in a slow, linear loss of cancellous bone mass with age 1, 10, 27, 31. It is generally 
thought that this thinning of the trabecular layer is associated with an age-related decline 
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Figure 3 | Prevalence of Osteoporosis and / or Low Bone Mass. Data was 
collected by The National Center for Health Statistics, part of the Center for Disease 
Control, displaying the number of men and women over the age of fifty with 
osteoporosis 10. 
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lost over this time. The change in cortical bone mass is more related to an increase in 
porosity rather than thinning. With age the porosity of cortical bone increases due to a 
decrease in radial closure of osteons, a reduction in osteon wall thickness, an increase in 
Haversian canal diameter, and the number of remodeling units aborted at the reversal 
phase 31. 
In men, this loss remains linear, but in females, the amount of bone loss 
accelerates with the onset of menopause. The exact mechanism behind bone loss in post-
menopausal women is unknown but it is thought that since hormones play an important 
role in the regulation of bone tissue remodeling, the marked decrease of estrogen levels in 
women during menopause has a great effect on this, usually regulated, process 10. This 
enhanced rate of bone loss in post-menopausal women is associated with an increase in 
bone turnover, not simply an acceleration of the normal age-related bone loss. In post-
menopausal women the loss of bone mass involves the complete removal of trabecular 
plates and a significant disruption in the trabecular lattice 31. Whole trabecular struts are 
resorbed, reducing the connectivity of the bone tissue and limiting the stress distribution 
within the tissue itself 31. The sudden and exponential decrease in estrogen levels within 
the body after the onset of menopause results in a fifteen percent decline in bone density 
10, 33, 34. It is this increase in trabecular resorption that enhances women’s chance of 
developing osteoporosis and experiencing a fracture during their lifetime.  
The exact pathology of osteoporosis is unknown, but there are many contributing 
factors causing the increased bone loss. One main factor in the reduction of bone mass is 
the inadequate intake and retention of calcium 33. As people age the intestinal absorption 
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and renal conservation of calcium is insufficient to conserve enough calcium to sustain 
blood levels. This retention rate is low due to the amount of calcium lost daily through 
shed skin, nail, hair, sweat, and urine. Because of all these factors, only four to eight 
percent of calcium is absorbed 33. This inadequate calcium intake contributes to 
osteoporosis by resulting in the thinning of the cortical layer as well as a decrease and 
thinning of trabeculae 33. In addition to changing estrogen and calcium levels, there are 
many age-related highly interdependent hormonal and nutritional factors that attribute to 
osteoporotic bone loss 35. Lastly, though the biochemical basis behind bone loss and 
osteoporosis is unknown, it has been discovered that there are many other diseases 
attributing to the increased bone loss. Some of these pathologies are hypercortisolism, 
gonadal insufficiency, thyroid disease, diabetes mellitus, hyperparathyroidism, as well as 
some gastrointestinal disorders 36.  
 
2.2.2. Paget’s Disease 
The second most common bone disease, Paget’s disease, is a progressive, and 
often crippling disorder that most often manifests in the sacrum, spin, femur, skull, 
sternum, or pelvis 10, 23. Paget’s disease results in an extremely disorganized bone 
structure that leads to an increased risk of fracture 23.  
Though Paget’s disease is the second most common bone disease, it affects far 
fewer people than osteoporosis. An estimated one million individuals in the United States 
suffer from Paget’s disease; affecting approximately 1.3 out of every one hundred people 
10. This disease is most often found within the spine, particularly the lumbosacral region, 
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and other bones within the axial skeleton 23. As with osteoporosis, Paget’s disease can 
lead to an increase in fracture risk, characteristically common in the femur and tibia 23.  
 The histopathology of Paget’s disease is characterized by three main 
physiological changes. Firstly, the bone tissue shows an abundance of osteoclasts and 
osteoblasts, resulting from an increase in bone turnover. The bone marrow is also invaded 
by a fibrous connective tissue with embedded blood vessels. Lastly, both cancellous and 
cortical bone display a disorganized structure, which has been termed “mosaic” 23. In 
early phases of the disease there is an increase in bone resorption activity. Both 
osteoclasts and osteocytes act to break down apatite crystals and collagen fibrils 23. This 
causes an increase in bone loss as well as a disruption of the bone structure within 
affected areas 10. In the second phase of the disease, bone formation amplifies to 
compensate for the induced bone resorption 10, 23. Due to the speed with which this new 
bone is laid down, mature bone is not formed; instead woven bone is present 10, 23. Woven 
bone is a more primitive bone tissue not normally found within the adult skeleton. This 
immature bone tissue has a disorganized alignment of apatite crystals and collagen fibrils 
10, 23. This woven bone that is laid down in response to the accelerated rate of bone 
resorption, causes the chaotic “mosaic” pattern within the bone structure 23. Also, within 
the active phase of Paget’s disease, the bone marrow is invaded by fibroblasts and 
mesenchymal cells acting to form a fibrous connective tissue within the bone marrow 
cavity 23. In the final phase of the disease, cellular activity ceases, but the affected area 
consists of dense woven bone tissue. This, now permanent, tissue is extremely 
susceptible to deformity and fracture 10. As such, common deformities seen with Paget’s 
 16 
disease are the bowing of weight bearing long bones and an enlargement of the skull 23. 
Most often Paget’s disease is painless, so it often goes undiagnosed until the occurrence 
of a traumatic fracture or the presence of severe deformity 23. 
As with osteoporosis, the exact cause of Paget’s disease is unknown. It is thought 
that Paget’s disease is caused by a combination of genetic and environmental causes, or 
possibly a virus 10. No single genetic abnormality has been discovered but between 
fifteen and forty percent of persons affected have a relative suffering from Paget’s 
disease 10.  
 
2.2.3. Microgravity Bone Loss 
The last pathology resulting in decreased bone mass and compromised structural 
integrity is caused by exposure to a weightless environment. The primary factor that 
causes bone remodeling is a change in mechanical stimulation, and when astronauts are 
exposed to the weightless environment of space, the induced bone remodeling leads to 
decreased bone mineral density 2, 27, 29.   
Virtually every astronaut on a mission longer than thirty days has experienced 
bone loss in a region of the skeleton 2. Prolonged space flight can cause a decrease in 
bone mass in the vertebrae, femur, pelvis, and hip at a rate up to 0.5% of bone mass lost 
per month 27. The lack of loading on the bones can cause a significant amount of bone 
loss, and the ensuing recovery takes two to three times the duration of the mission 2.  
Microgravity bone loss does not involve specific pathological changes within the 
body. The decrease in bone density occurs as part of a natural remodeling process, 
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without mechanical loading on the bone, the body resorbs the tissue due to a lack of need 
2, 27. Smith et al. showed that bone resorption increased approximately fifty percent 
during space flight 4. Weight-bearing bones experience the most loss due to the severe 
change in the loading conditions, while nonweight-bearing bones undergo less resorption 
27. A study performed in conjunction with a three-month space flight displayed an 
average decrease in bone mineral density of 2.5%, 8.2%, 5.0%, and 6.2% in the tibia, 
greater trochanter, femoral neck, and lumbar vertebrae respectively 3. 
In addition to a lack of mechanical stimulation there are a few other conditions of 
space travel that lend to a decrease in bone mass. During spaceflight there is a lack of 
exposure to UV light, diminishing the reserves of vitamin D within the body 2. Also 
decreased levels of calcium absorption and hormones in the blood occur in response to 
bone resorption, limiting subsequent formation 2. The body loses about 250mg of calcium 
per day, mainly due to increase in urinary calcium excretion 4. NASA and other 
spaceflight organizations have implemented many different countermeasures to prevent 
bone loss. Mainly exercise, increased calcium or phosphate intake, vitamin D 
supplementation, exposure to UV light, and administration of early generation 














3.1. Anti-Catabolic Therapeutic Approaches:  
An In Vitro / In Vivo and Clinical Overview 
Diseases of bone resulting in mineral loss and an increased risk of fracture can be 
detrimental to the patient as well as the health care system, due to such high costs. But 
there are many ways to treat these diseases including some diet and lifestyle changes. 
There are many nutrients that can affect bone and calcium homeostasis, such as calcium, 
vitamin D, phosphorous, and sodium 2. Adequate dietary intake of calcium is essential for 
sufficient bone mineral density for it slows the rate of bone resorption. Vitamin D plays a 
major role in preventing calcium deficiency through direct effects on the intestines, 
kidney, parathyroid gland, and bone 28. Circulation of 25-hydroxyvitamin D (25 [OH]D) 
indicates the status of vitamin D activity, levels of with should be between seventy-five 
and one hundred nanomolar per liter for optimal fracture prevention 43. In addition to 
dietary changes, non-pharmalogical lifestyle changes can aid in the prevention and 
treatment of such bone diseases. It has been shown that weight-bearing exercises such as 
aerobics can help postmenopausal women prevent at least two percent of bone mineral 
density loss 43. 
Though dietary and lifestyle changes can help with treatment, many times patients 
need a therapeutic approach to either prevent bone loss, or help lay down new bone 
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tissue. There are three basic criteria used in the initiation of pharmacologic treatment of 
osteoporotic bone loss. [1] History of an osteoporotic vertebral or femoral fracture, [2] a 
T score equal to or worse than -2.5 in the lumbar spine, femoral neck, or total hip region, 
lastly [3] a T score from -1.0 to -2.5 with a risk of osteoporotic fracture of at least twenty 
percent 43. The National Osteoporosis Foundation recommends that a patient meeting any 
one of the aforementioned three criteria be considered for pharmalogical treatment 43.  
There are two main methods for the treatment of bone diseases such as 
osteoporosis, Paget’s disease, and microgravity bone loss; these are an anti-catabolic and 
an anabolic approach. Anti-catabolic bone treatments block the activity of osteoclast cells 
to prevent bone resorption and remodeling. This approach does not increase the amount 
of bone; its focus is to prevent any further pathological loss of bone structure 43, 52-56. 
Anabolic methods of treatment focus on inducing osteoblasts to lay down new ECM, to 
be mineralized and increase the skeleton bone mineral density. The goal of these 
therapies is to replace any lost tissue with new mineralized bone 8, 10, 12, 25. There are 
multiple anti-catabolic and anabolic therapies either in current use or being researched.  
 
3.1.1. Bisphosphonates 
The most common drug therapy available for treatment of bone loss is a class of 
anti-catabolic drugs called bisphosphonates, these therapies are considered as a first-line 
treatment 43. They work to inhibit bone remodeling, including both the resorption and 
formation processes 43, 52, 56. This results in reduced cortical porosity, improved bone 
mineralization, and structural maintenance of trabecular and cortical bone 43. 
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Bisphosphonates act to prevent future bone loss and retain the current bone structure. An 
overview of current commercially available bisphosphonates, such as alendronate, 
risedronate, ibandronate, and zoledronic acid, can be found in the table below. Some 
additional bisphosphonate formulations are clodronate, etidronate, incadronate, 
minodronate, olpadronate, pamidronate, and tiludronate. 
Bisphosphonates have a marked affinity to bind to the surface of calcium 
phosphate hydroxyapatite crystals. Bisphosphonate molecules thermodynamically prefer 
to be bound to calcium phosphate, creating a strong binding preference 64. These 
bisphosphonates surround the bone and act directly on osteoclasts by inhibiting 
recruitment and adhesion to the mineral matrix, shortening the osteoclast lifespan and 
directly inhibiting the cellular activity 98. Through all these methods, bisphosphonates 
prevent further bone loss once engulfed by the catabolic cells during remodeling 43, 52. 
Bisphosphonates contain a phosphate – carbon bond that is resistant to most chemical 
agents and is inert to enzymatic degradation. Since these molecules cannot be broken 
down, they accumulate in the osteoclasts and result in substantial toxicity 98. In vitro 
bisphosphonates alter the osteoclastic activity by inhibiting the initial act of bone 
remodeling, formation of pits in the mineralized substrate 52. Bisphosphonates produce 
the same effect in vivo, but there is a poor correlation between in vitro and in vivo 
bisphosphonate efficacy 52. In normal animal models bisphosphonates blocked the 
degradation of both bone and cartilage tissue by suppressing the remodeling process. This 
effect results in a radiologically denser club-shaped bone 52. Though bisphosphonates do  
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Bisphosphonate Brand Name / Company Delivery Indications Bioavailability Adverse Effects 
Alendronate Fosamax / Merck Oral Prevention 5mg daily or 







Cautious use with 




10mg daily or 
70mg once weekly 
Alendronate + 
cholecalciferol 
Fosamax Plus D / 
Merck 
Oral Treatment 70mg + 2800 units 
per week or 70mg 
+ 5600 units per 
week 
Musculoskeletal pain 





5mg daily, 35mg 
once weekly, 
75mg in two 
consecutive days 









Cautious use with 











then 6 days 
1250mg calcium 
Muscular / joint pain, 
constipation, nausea 













Cautious use with 
ASA or NSAIDs 
Intravenous Treatment 3mg every 3 
month 
Musculoskeletal pain, 
pain in extremity, 
diarrhea, headache 






every two years 
Treatment: 5mg 
annually 
Muscular / joint pain, 
pyrexia, flu-like 




Table 2 | Bisphosphonate Overview. Currently available bisphosphonate therapies 43. 
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not act to increase bone formation, they often result in a small increase in bone mineral  
density. This is caused from an uncoupling of the resorption and formation processes. In 
normal bone, the amount of resorption and formation are kept in check with each other. 
But when the resorption process is blocked, these two processes because temporarily 
uncoupled, allowing formation to continue for a period of time, resulting in a small 
increase in bone density 43, 52. X-ray imaging is commonly used to determine the 
effectiveness of bisphosphonates by viewing the change in density and shape, known as 
the Schenk assay. This effect was also seen with all available bisphosphonate formation 
in in vivo osteoporotic mouse models 52. The mechanical properties of bone treated with 
bisphosphonates were tested in both normal and osteoporotic animal models. It was 
shown that, when given in appropriate doses, an improvement in bone biomechanical 
properties in both normal and diseased models was observed. Bisphosphonates are shown 
to improve torsional torque, ultimate bending strength, stiffness, maximum elastic 
strength and Young’s modulus of elasticity 47, 52.  
Bisphosphonates are the most common treatment in its drug class, coming in both 
oral and intravenous formulations. They are seen as an appropriate and cost-effective 
therapy for both the treatment and prevention of osteoporosis 43, 47. Clinical studies have 
shown that bisphosphonates can increase vertebral bone mineral content by 5.3%, while 
patients receiving the placebo experienced a 2.7% loss of mineral density 67. These drugs 
also efficiently reduce the rate of fracture after only fifty weeks of treatment; fracture 
rates were decreased from fifty-four to six fractures per every 100 patients 67. Since these 
drugs have such a high affinity for the calcium phosphate crystals within the bone, it has 
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been shown that once treatment ceases, the beneficial effects can been seen for up to five 
additional years 43. This high binding affinity due to a thermodynamic driving force is 
enough to allow the bisphosphonates to efficiently target bone, due to the exponentially 
higher calcium phosphate concentrations than elsewhere in the body. Though these 
molecules effectively target bone tissue, oral bisphosphonates have a poor bioavailability, 
with less than one percent of drug reaching the bone 82. Intravenous bisphosphonate 
formulations, on the other hand, allow about half of the dose to be taken up and retained 
by the skeleton 85. 
In addition to the reduction of bone resorption, bisphosphonates are also used to 
treat hypercalcemia, or increased blood calcium levels, in metastatic cancer patients to 
prevent osteoid deposit in cancerous tumors 66, 97. These drugs have been shown to lower 
blood serum calcium levels by preventing osteoclasts from removing calcium reserves 
from the bone and depositing them in the blood supply 97. A side effect of this therapy 
though can be a pathological lowering of the blood calcium levels, hypocalcemia, which 
can cause uncontrolled muscle contractions and cardiac arrhythmias 66. 
These drugs are approved for long-term use, but there are some adverse effects 
that have been seen 52. The only side effect common to oral bisphosphonates is the 
inflammation and ulceration of the upper gastrointestinal tract, which can be avoided by 
using intravenous formulations 85. The most common side effect with bisphosphonate use 
is acute inflammatory reactions, characterized by mainly by a low-grade fever. Recently 
it was reported that fifteen to thirty percent of patients receiving bisphosphonates 
experience a fever after an intravenous injection, with the risk varying due to patients’ 
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underlying diseases 65. More serious systemic side effects associated with 
bisphosphonates are ocular inflammation, atrial fibrillation, idiopathic fractures of the 
femoral diaphysis, renal failure, and osteonecrosis of the jaw 43, 56, 65. In clinical trials 
these complications generally occurred in less than two percent of patients, but recently 
the occurrence has increased. Ocular complications such as conjunctivitis, scleritis, eyelid 
edema, and inflammation have an estimated incidence of 0.05% 65. Bisphosphonates have 
also been linked to increasing the chance of atrial fibrillation from a 0.5% risk to a 1.3% 
risk 43. Patients have also experienced subtrochanteric and diaphyseal fractures, both of 
which have an unknown cause, but a link has been made to bisphosphonate use. Though 
uncommon, the FDA has recommended bisphosphonate manufacturers alter the warning 
label on currently available medicines 103. Some of the more serious complications, renal 
failure and osteonecrosis of the jaw, are more commonly seen in patients receiving high 
bisphosphonate doses for the treatment of metastatic cancer 82, 95. Bisphosphonates are 
excreted unchanged by the kidneys, processing of these molecules is shown to cause 
damage to the proximal tubule and cause acute tubular necrosis 96. With continued 
bisphosphonate use, renal failure can commonly occur, but with careful monitoring and 
dosing these chances can be lowered 96. In addition to renal failure, the higher doses of 
bisphosphonate treatments commonly given to cancer patients are known to cause 
osteonecrosis of the jaw. This side effect is only seen in healthy patients at a rate of one 
out of every 10,000 to one of every 100,000 cases 43. But recent statistics estimate that 
approximately two percent of cancer patients being treated with intravenous 
bisphosphonates develop osteonecrosis of the jaw 82. Despite the recent increase in 
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systemic side effects, bisphosphonates are still the most commonly prescribed treatment 
for bone diseases due to the effective retention of osteoporotic bone mass, slowing of 
bone turnover in Paget’s disease, and lowering of blood calcium levels is patients with 
cancer 43, 47, 65, 66. 
 
3.1.2. Hormone Therapy 
Estrogen, and the lack thereof, plays a large role in the onset of post-menopausal 
osteoporosis, and can also be used as a treatment option to prevent further development 
of the disease 43. Estrogen hormone therapy is an anti-catabolic treatment shown to not 
only preserve current bone mass, but the first one to two years of treatment often result in 
an increase in measured bone density 53. Currently, estrogen treatment therapies come in 
various formulations and methods of delivery 43, 53.  
On the cellular level, estrogen binds to osteoclast receptors and stimulates the 
release of mediators that block further osteoclast activity 43. In the initial weeks of 
therapy, biochemical markers of bone resorption slowly decline, followed by a slow and 
delayed decline in bone formation markers 53. In addition to a decreased resorption, 
estrogen also acts to rapidly reduce the activation of new remodeling sites within the 
bone 53.  
Estrogen hormone therapy can be used for both the prevention and treatment of 
osteoporosis in post-menopausal women. It is shown to reduce the occurrence of both 
vertebral and non-vertebral fractures by thirty percent. Since estrogen is a naturally 
occurring molecule, it is distributed evenly throughout the body protecting the whole 
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skeleton from further bone loss 43. Estrogen therapy has many proven benefits, but 
recently many serious side effects have been discovered. The Women’s Health Initiative 
performed a randomized trial to investigate potential effects of long-term estrogen 
therapy (HERS); their results eliminated hormone therapy as a first-line option. Hormone 
replacement therapy was linked to an increase in thromboembolic event and strokes, as 
well as an increased risk of breast cancer 10, 44, 56, 68, 69. Though estrogens used for the 
treatment of postmenopausal osteoporosis only have the biological potency of one-fourth 
to one-fifth of modern contraceptives, they have similar thrombotic risks 68. In a placebo-
controlled study, women in the placebo group had thromboembolic events occur 2.3 
times per 1000 women-years. While the group receiving hormone therapy experienced an 
elevated risk of 4.0 per 1000 women-years 68. As for the increased risk of breast cancer 
development there is no direct evidence, only observational correlations. It has been 
proposed that hormone replacement therapy can act as a promoter of already initiated 
breast tumors 70. This is evidenced by the 8.8% annual decline in breast cancer 
occurrence with a 6.8% reduction in the use of hormone replacement therapy 70. One 
group proposed that women receiving hormone replacement therapy have a 2.5 times 
higher risk of developing breast cancer 69, while another estimated a twenty to fifty 
percent higher risk 80 than those who do not receive this treatment. Because of these 
results, The North American Menopause Society and The Endocrine Society recommend 
hormone replacement therapy not be used for chronic disease prevention because the 
risks far out weight the benefits 43, 56. They also recommend that estrogen therapy only be 
used for women at low risk for coronary heart disease, various cancers, and stroke who 
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are recently menopausal, these patients have a more favorable benefit to risk ratio 43, 56. 
After the HERS study the prescribing of hormone therapy has steadily decreased, and 
more emphasis has been put on other forms of osteoporosis treatment 73.  
 
3.1.3. Estrogen Agonist / Antagonist 
Another type of hormone-related anti-catabolic therapy for the treatment of 
various bone diseases is an estrogen modulator, raloxifene. Raloxifene, made by Eli Lilly 
& Co.,marketed under the name Evista, is approved as a first-line treatment of both 
prevention and treatment of bone loss 43. This benzothiopene derivative reduces bone 
resorption by mimicking estrogen’s beneficial effects within bone, while having an anti-
estrogen effect on the breast and uterus. These estrogen modulators also tend to lower 
serum cholesterol levels 43, 57. Raloxifene is commonly prescribed because it provides the 
beneficial aspects of estrogen hormone therapy without the associated serious adverse 
effects.  
Raloxifene acts by binding to estrogen receptors in the body and inhibiting the 
effects of estrogen on the uterus, while inducing estrogen-like effects on bone tissue 57. In 
osteoporotic mouse models, raloxifene blocked the decline of bone mineral density, when 
compared to non-treated controls, at concentrations as low as 0.1mg/kg 57. The ensuing 
effect on the bone was indistinguishable from those in animals treated with estrogen 
therapy 57. While this drug had similar effects on the bone as estrogen, the two treatments 
diverged because raloxifene lacked a significant effect on the uterus and breast in that 
they do not increase the risk of cancer in these tissues 57. Hormone therapy is known to 
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increase the risk of breast cancer, endometrial, or uterine, cancer was also common 
before the addition of progestin to estrogen treatments 57. 
Raloxifene has been shown to improve bone mineral density in the lumbar spine, 
lowering the risk of vertebral fractures thirty to fifty percent, but there is no evidence for 
the protection from non-vertebral fractures 43. In addition to raloxifene’s effect on the 
bone, it has also been shown to decrease the chance of cancer in the breast and uterus 43. 
A study on breast cancer, called the Continuing Outcomes Relevant to Evista (CORE), 
found a fifty-nine to sixty-six percent reduction in the risk of breast cancer after eight 
years of treatment due to the drug’s anti-estrogen effects 46. Though this treatment 
reduces cancer risk, unlike estrogen, due to raloxifene’s similarity to estrogen, it has 
some of the same associated risks such as an increase in thromboembolic events 43, 56.  
For this reason The North American Menopause Society recommends the use of 
raloxifene for younger women who are more at risk of vertebral, rather than hip fractures. 
Also younger women are much less likely to have comorbid illnesses that can contribute 
to the risk of a thrombus formation 43, 56.  
Currently, Pfizer, in collaboration with Wyeth and Ligand Pharmaceuticals, is 
performing clinical trial to get approval by the Federal Drug Administration for two new 
estrogen agonist / antagonist. Pfizer and Ligand Pharmaceuticals have been working to 
get FDA approval on a new hormone treatment called lasofoxifene 43. Under the brand 
name Fablyn, lasofoxifene has been sold in the European Union since its approval in 
March 2009 43. In clinical trials lasofoxifene was associated with a reduction in the risk of 
vertebral fractures, non-vertebral fractures, estrogen receptor-positive breast cancer, 
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major coronary heart disease events and stroke 71. Lasofoxifene has the potential to be a 
better treatment than raloxifene because it has proven beneficial effects on the non-
vertebral fracture occurrence 71. Pfizer is also working with, their now subsidiary, Wyeth 
to obtain approval on another estrogen modulator bazedoxifene. Bazedoxifene has been 
shown to have similar results as raloxifene in reducing vertebral fractures up to forty-two 
percent but shows no reduction in the risk of non-vertebral fracture in average 
osteoporotic patients 72. Bazedoxifene does lower the incidence of non-vertebral fracture 
in patients at elevated risk, an advantage over raloxifene 71. Currently in Phase III clinical 
trials, bazedoxifene will be marketed in the United States with the brand name Vivant. 
Again, this therapy is already approved for sale and use in the European Union under the 
name Conbriza 43.  
 
3.1.4. Calcitonin 
Calcitonin is a polypeptide hormone used as an anti-catabolic second-line 
treatment for patients who do not respond or have intolerable reactions to first-line 
treatments 43. Calcitonin is used to inhibit further bone resorption normally in women 
who are more than five years post-menopausal 43. Calcitonin was also the first effective 
treatment for Paget’s disease; it lowers biochemical markers for bone turnover thirty to 
fifty percent, relieves bone pain, and also leads to healing of pagetic lesions 54. Calcitonin 
is commercially available as a nasal spray under the names Fortical and Miacalcin by 
Upsher-Smith Pharmaceuticals and Novartis, respectively. But these therapies are not 
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commonly used because though they are one of the safest therapies, they are also far less 
effective and have a much shorter duration than other treatments 54-56.  
Calcitonin treatment acts directly on osteoclasts to inhibit both basal and 
stimulated resorption by causing a rapid loss of the cell’s ruffled border. This peptide 
induces an acute cessation of osteoclast cytoplasmic motility by gradual pseudopodial 
retraction, leading to an inability to transform the plasma membrane to an active 
conformation 54. Calcitonin also inhibits osteoclastic acidic secretion of tartrate-resistant 
acid phosphatase (TRAP) and Na+-K-- ATPase necessary for mineral and collagen 
breakdown 54. Studies have shown that with an extended treatment term, the number of 
osteoclasts eventually decreases 54. This defined cascade of biological responses to 
calcitonin results in a reproducible repression of bone resorption 54.  
Calcitonin produces effective cessation of bone resorption, but this effect 
generally does not last more than 24 hours, of which the direct affect on osteoclasts’ 
function membrane and secretions only lasts for several hours 54. Osteoclasts resume 
normal function in between calcitonin uses, causing this reproducible biochemical 
process to have variable results 54, 55. When prescribed and used correctly, calcitonin is 
able to prevent bone loss and lower the incidence of vertebral fracture, but it is seen as 
clinically impractical due to a need for strict patient compliance 54. It is generally only 
used for women at least five years post-menopausal who either cannot or choose not to 




The last anti-catabolic therapy for the treatment of bone loss is denosumab, an 
antibody that interacts with biological proteins in order to prevent bone resorption 43. This 
treatment is made by AMGEN and marketed under the brand names Prolia and Xgeva. 
Though this isn’t a common treatment for osteoporosis, it has been shown to be very 
effective at blocking bone loss. 
Denosumab is a human monoclonal antibody that binds to the receptor activator 
of nuclear factor-kappa β ligand (RANKL). The protein RANKL is essential to the 
formation and function of osteoclasts, with the binding of denosumab this protein is 
deactivated 43. The inhibition of this protein leads to a blockage of bone resorption 43. 
Denosumab works in a similar way as bisphosphonates, this antibody targets a different 
step in the bone remodeling process, but had produced very similar results in animal trials 
43.  
A clinical trial was performed called The Fracture Reduction Evaluation of 
Denosumab in Osteoporosis Every Six Months (FREEDOM) evaluating the efficacy of 
the therapy. A three-year randomized double-blind study with 7868 participants reported 
significant success. Denosumab reduced the risk of vertebral fracture by sixty-eight 
percent, hip fracture by forty percent, and resulted in a twenty percent reduction in all 
other non-vertebral fractures 45. This anti-catabolic treatment only has a few side effects, 
mainly back and muscle pain 56. A possible complication associated with denosumab, is 
the lack of studies on the long-term effects of disrupting the RANKL receptor sites. It is 
known that these ligands also play a role in the immune system 43.  
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3.1.6. Benefits and Limitations of Anti-Catabolic Treatments 
 Each year 1.5 million people in the United States suffer from an osteoporotic-
related fracture, making it essential to preserve bone mass and structural integrity while 
reducing the risk of a traumatic fracture 10. Anti-catabolic therapies are the most widely 
prescribed treatments in the United States for the treatment and prevention of 
Therapy Brand Name / Company Delivery Indications 
Bioavailabil
ity Adverse Effects 
Hormone Therapy Many Oral Treatment 0.625mg 
daily 
Abdominal pain, 
headache, heart attach, 
stroke, pulmonary 
emboli, breast cancer 
Transdermal 
Estrogen Agonist / 
Antagonist 





(up to 40 
months) 
Leg, cramps, hot 
flashes, 
thromboembolic events 















Nasal 200IU daily Nasal discomfort 
Denosumab Prolia / AMGEN Subcutaneous Treatment 60mg every 6 
months 
Muscular pain 
Teriparatide Forteo / Eli Lilly 
& Co. 
Subcutaneous Treatment 20µg daily 




Table 3 | Available Anti-Catabolic Treatments. Currently available anti-catabolic therapies 43, 76. 
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osteoporosis, mainly bisphosphonates 10, 43. These anti-catabolic treatments are extremely 
effective in lowering the risk of both vertebral and non-vertebral fractures and ceasing the 
bone resorption process. Risk of fracture is lowered up to sixty-eight percent and in some 
cases the bone mineral density can even increase around five percent 43, 45, 67. In some 
treatment forms, such as estrogen agonist / antagonists, these effects can be seen with 
very low dosages and after less than one year of treatment 57. Though these treatments are 
very effective and commonly used, they focus on retaining the density and structure the 
bone has at the initiation of treatment. If therapy is started at a more progressed stage of 
the disease, anti-catabolic treatments many not be as effective. Since these drugs act to 
prevent further damage they are very effective when administered early in the disease 
progression, but for patients with severe bone loss, an anabolic therapy may be more 
desirable 43, 52.  
 
3.2. Anabolic Therapeutic Approaches:  
An In Vitro / In Vivo and Clinical Overview 
 
3.2.1. Teriparatide 
Parathyroid hormone naturally plays a role in the body by maintaining calcium 
levels and stimulating both bone formation and resorption 10. As a therapeutic treatment, 
recombinant forms of parathyroid hormone have been shown to have anabolic properties 
and act to rebuild bone tissue 43, 56, 58. Currently, the available parathyroid hormone 
therapy is a recombinant intravenous injectable drug teriparatide, made by Eli Lilly & 
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Co., with the brand name of Forteo. There are also competitor forms of recombinant 
parathyroid hormone in clinical trials 43, 58.  
Teriparatide and recombinant forms of parathyroid hormone act in a similar 
manner as the natural molecule, they act to activate bone turnover throughout the body 43, 
56, 58, 59. Studies have shown that biochemical markers for bone turnover are elevated 
throughout the blood indicating a global response to the treatment. Also the increase in 
bone mineral density seen as a result of the therapy proves a continuous effect on the 
coupling of formation and resorption, causing a balance in the favor of formation 59. The 
early increase in bone mineral density suggests a rapid stimulation of osteoblastic activity 
through the activation of existing osteoblasts and the induction of differentiation of bone-
lining cells 59. Another advantageous effect seen from the use of teriparatide is the lack of 
influence of other hormones. Fluctuating levels of estrogen and testosterone constantly 
influence natural parathyroid hormone, while the responsiveness of osteoblasts was 
unchanged with teriparatide 59.  
In application, teriparatide has shown strong clinical success in the induction of 
bone growth and remodeling. It has been shown that the bone mineral density of the spine 
is increased by 8.6% and that of the femoral neck increased by 3.5% 43. Also, more 
significantly, a sixty-five percent reduction in vertebral fracture and a fifty-three percent 
decrease in non-vertebral fracture risk were seen with the use of teriparatide treatment 43, 
76. In a study comparing teriparatide and bisphosphonate, the bone mineral density 
measurements and biochemical markers for bone turnover were higher with teriparatide 
treatment 86. It was thought that the anti-resorptive action of bisphosphonates could be 
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combined with the anabolic effects of teriparatide. But this same study demonstrated that 
when used together, bisphosphonates hinder teriparatide’s ability to increase bone 
formation, indicating that resorption plays a large role in teriparatide’s ability to enhance 
bone formation 86. A possible issue with this form of treatment may arise from future 
studies. There are currently no studies proving the long-term efficacy and safety of 
teriparatide 43, 56. Because of this lack of data, teriparatide is generally only prescribed to 
patients with extremely low bone mineral density and for only a maximum of two year 43, 
56. Upon the cessation of this hormone treatment, without further treatment many patients 
experience substantial bone loss. Commonly, bisphosphonates are required to prevent 
loss of the newly formed bone tissue 43, 56, 74. In a study of patients undergoing one year 
of treatment with teriparatide then one year of alendronate therapy showed increased in 
bone mineral density in both cortical and trabecular bone 74, 75. Cancellous bone 
experienced a thirty-one percent increase in volumetric mineral density, all of which was 
retained due to the anti-resorptive bisphosphonate administration 74.  
Another form of recombinant parathyroid hormone is under investigation for 
possible approval by the FDA for use in the United States. NPS Pharmaceuticals 
formulated a fully human recombinant hormone, PTH (1-84) 43, 58. This new drug is 
shown to reduce the risk of new or worsened vertebral fractures. In a study of 2532 
postmenopausal women, PTH (1-84) increased the bone mineral density of the spine and 
hip 6.9% and 2.1%, respectively. These increases in density were accompanied by a 
concurrent loss in bone mineral density of the forearm as well as an increase in 
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hypercalciuria, hypercalcemia, and nausea by 24%, 23%, and 14% respectively 58. This 
treatment is currently approved for use in the European Union 43.  
 
3.2.2. Statins 
Statins are a class of commonly prescribed drugs that act as competitive inhibitors 
of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase in order to decrease 
hepatic cholesterol biosynthesis. These molecules acts as a rate limiting step in 
cholesterol synthesis by blocking conversion of HMG-CoA to mevalonate, resulting in 
lowered serum cholesterol levels for the treatment of high cholesterol and coronary heart 
disease 12, 49. Recently, studies have shown that statins also increase the expression of 
bone morphogenic protein 2 (BMP-2) in osteoblasts, inducing osteoblast differentiation, 
and subsequently stimulating bone formation 8, 25, 49. These treatments are currently being 
investigated and researched by many different groups for possible use as a therapy for 
bone loss, reversing the acquired skeletal fragility.  
Statins induce bone formation by enhancing expression of various biological 
proteins associated with bone cells. In culture of both murine (2T3) and human (MG-63) 
bone cells, statins enhanced the expression of the BMP-2 mRNA, which has been shown 
to be the most potent inducer of osteoblast differentiation 12, 25. These cholesterol-
lowering drugs also increased the expression of type 1 collagen mRNA while 
concomitantly lowering the expression of collagenase in MC3T3-E1 mouse osteoblast 
cells 18. Increased collagen availability further enhances the ability for newly 
differentiated osteoblasts to lay down osteoid. Alkaline phosphatase, necessary for bone 
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mineralization, concentration was also elevated in cells treated with statin drugs 18, 20. 
Osteoblastic differentiation, availability of collagen, and presence of alkaline phosphatase 
all act to increase the number of bone forming regions to allow an increase trabecular 
bone volume between thirty-nine and ninty-four percent 12. When tested in animal 
models, lovastatin, simvastatin, fluvastatin, and mevastatin all increased new bone 
formation two to three fold. This increase is comparable to treatment with BMP-2, the 
main component inducing osteoblast activity 12. While BMP-2 is highly effective in 
inducing bone formation, it is not an ideal treatment because it is very expensive to 
manufacture 84. 
One of the few clinical studies performed with statins consisted of 1003 
postmenopausal women in the United Kingdom. The results showed that the bone 
mineral density seen in both the hip and the spine remained significantly higher in the 
experiment group as compared to the control 42. Though much of the clinical information 
on statins comes from observational studies, it is enough to provide a solid correlation 
between the use of statins and the reduced risk of fracture and increased bone mineral 
density.  
 
3.2.3. Stronium Ranelate 
The last treatment option widely researched is strontium ranelate, a conjugate of 
strontium and ranelic acid 43, 60-63. The mechanism of action behind strontium ranelate is 
not well known. In vitro and in vivo, it has shown both anabolic and anti-catabolic 
properties, it is proven to both increase bone formation and decrease resorption 43, 60-63.  
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While not approved for sale in the United States, an oral form of strontium ranelate is 
marketed for use in prevention of vertebral and hip fractures abroad by Servier under the 
name Protelos 43.  
Research into the direct mechanism of strontium ranelate has shown that 
treatment of mouse calvaria bone cells for twenty-two days resulted in increased 
expression of multiple osteoblast markers, as well as an increase in number of bone 
nodules 60. Strontium ranelate has also been associated with a decrease in the numbers of 
mature osteoclasts and bone resorption 60. It is thought that this decrease in bone 
resorption is achieved by strontium ranelate’s total disruption of the actin cytoskeleton of 
osteoclasts. The disruption of this protein structure prevents the cells from attaching to 
the apatite minerals, a necessary step in the mineral breakdown 60. Animal studies have 
also proven the efficacy of strontium ranelate as an anabolic bone agent. Intact rats given 
a dose of ninety milligrams per kilogram per day showed an increase in cortical and 
trabecular bone volume, microarchitecture, and total alkaline phosphatase activity, an 
indication of bone-forming activity 63. Strength of both cortical and trabecular bone 
increased, this was associated with improvements in the micro-architecture in both tissues 
60.  
In clinical trials, strontium ranelate decreased the risk of fracture as well as 
increased patients’ bone mineral density 61, 62. It was shown that a dose of two grams per 
day decreased the relative risk of non-vertebral fractures by sixteen percent 62. Among 
women with a high risk of fracture, the prevalence was reduced thirty-six percent in the 
hip and thirty-nine percent in the vertebrae 62. Strontium ranelate, at the same dosage, 
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increased the bone mineral density in the lumbar spine by 14.4% and in the femoral neck 
by 8.3% after thirty-six months of treatment 61.  
 
3.2.4. Benefits and Limitations of Anabolic Treatments 
The ability to enhance bone mineral density and repair pathological damage is an 
optimum treatment path for bone disease therapies. The only anabolic treatment approved 
for use in the United States is a form of recombinant parathyroid hormone, teriparatide 10, 
43, 58. Teriparatide is approved for up to two years of use, resulting in increased bone 
mineral density up to 8.6% 43. Though teriparatide is very effective at increasing bone 
density, upon cessation of treatment bisphosphonates are needed to prevent continued 
breakdown of the tissue 74. Statins have shown remarkable success in the induction of 
bone formation through the increased expression of biological markers, but much more 
research must be completed before this can be considered a potential treatment for bone 
pathologies 12, 18, 25. Lastly, strontium ranelate acts in two ways to increase formation and 
decrease resorption and has shown increases in bone density 61. The mechanism behind 
this therapy is not well known or understood, but with further research strontium ranelate 
may be approved as an effective therapy by the FDA 60.   
 
3.3. Controlled Delivery 
 
3.3.1. Nanoparticle Delivery Vehicles 
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Nanoparticles are commonly investigated for their ability to transport drug 
therapies and release the treatments directly into the cell. These nanoparticles are so 
effective because they are much smaller than a cell; these particles are taken up by the 
cell, transported across the cell membrane, and released into the cytosol for delivery to 
cell organelles 11. Many materials are being researched for the fabrication and loading of 
nanoparticles. A large focus has been placed on polymers because of the lack of 
inflammatory or immune response, and the proven biodegradability of some bioinert 
polymers 11. For therapeutic delivery to bone tissue, an emphasis has been placed mainly 
on three different polymers, N-(2-hydroxypropyl)methacrylamide copolymer (HPMA), 
polyurethane (PU), and poly(lactide-co-glycolide)-poly(ethylene glycol) copolymer 
(PLGA-PEG).  
HPMA copolymer nanoparticles were successfully formulated with a proper 
molecular size such that they were efficiently cleared from the body by the liver, with 
minimal accumulation in the heart and lungs 90. It has been shown that a larger molecular 
weight increased the particle accumulation in bone, but decreased the specificity of the 
targeted delivery 99. These HPMA particles were also used to deliver prostaglandin, 
known to have anabolic effects on bone, to the tissue with a large portion of the drug 
being release in the cellular osteoclast environment 100, 101. Biodegradable PU scaffolds 
have also been a topic of research for the delivery of statins to bone tissue. The use of a 
scaffold prevents a large amount of the drug from being lost due to first-pass metabolism 
93. It was shown that two hundred micrograms of lovastatin was a sufficient dose to 
enhance new bone formation without any adverse inflammatory reactions 93. Groups are 
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also looking into using known biocompatible polymers for bone drug delivery such as 
PLGA-PEG. PEG is commonly used in nanoparticle formulations to provide additional 
biocompatibility and increased blood circulation time compared to non-PEGylated 
particles 102. Avgoustakis et al. showed that PLGA-PEG particles remained in systemic 
circulation for hours, while particles without PEG conjugation were removed from 
circulation within minutes 102. It was also showed that altering the proportions of PLGA 
to PEG within the copolymer could change the biodistribution of the particles 102.  
Rather than using inert polymers, an emphasis has also been placed on the use of 
physiological materials such as hydroxyapatite and other calcium orthophosphates for the 
delivery of drug therapies, especially to bone tissues. Hydroxyapatite and other calcium 
phosphate molecules are chemically similar to the inorganic component of bone, eliciting 
no immune response and allowing them to chemically bond to the bone tissue 6, 40. 
Because of the chemical likeness to native bone tissue, the use of hydroxyapatite as a 
particle allows for targeted delivery for, these particles preferentially deposit in bone 
tissue. Once these particles bind to the bone they are actively transported into bone cells 
where the loaded drug can be released for treatment of various conditions 6. It has been 
shown that a portion of the particles escapes the phagocytic pathway and directly enters 
the cytoplasm for efficient quick delivery 6. In addition to allowing for targeted delivery 
of drug, the nano-crystalline structure of hydroxyapatite particles has been shown to 
stimulate bone proliferation and growth 13. For all these reasons hydroxyapatite and other 
calcium phosphate materials are seen as potential candidates for slow release vectors, 
while being investigated for drug delivery and bone stimulation 6. 
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3.3.2. Targeting Approaches 
In order to enhance specificity of polymer and hydroxyapatite delivery to bone, 
many different targeting techniques have been investigated. Delivery specificity is 
extremely important because drug absorption in unwanted tissues can cause serious 
adverse effects, as was the problem with estrogen therapy 98. There are two main 
approaches to locally targeted drug delivery with nanoparticles, passive and active 
targeting 11. Passive targeting is often used for delivery to tumors because it utilizes 
characteristic physiological tumor biology. Tumors experience an increase in vascular 
fenestrations due to the enhanced permeability and retention effect, allowing for the 
increased delivery of nutrients to the tumor due to the accelerated growth rate 11. Passive 
targeting relies on this increased permeability to allow for more nanoparticles to be 
delivered to the tumor site 11. Though effective, passive targeting is difficult to control 
because of the randomness of the approach. For delivery to non-tumorous tissues active 
targeting must be utilized. Active targeting approaches use the conjugation of small 
molecules to the surface of the nanoparticles. These molecules are specially chosen to 
bind to overexpressed antigens or receptors at the site of targeted delivery 11. Targeting 
agents generally fall within one of the following categories: proteins, including 
antibodies, nucleic acids, peptides, vitamins, or carbohydrates 11.  
Targeting of bone tissue would allow for particles to accumulate in the skeleton, 
improving the pharmacokinetic profile and therapeutic effects of the drug 98. Bone is seen 
as a difficult target due to the low blood flow rate, only 0.05-0.2ml/min/g, and the tissue 
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composition 88. Bone contains a large portion of type I collagen, but this would not be a 
suitable molecular target because it is ubiquitous throughout the body, so the mineral 
component, hydroxyapatite, remains the most suitable target 98. There are many 
molecules used to provide bone targeting specificity, mainly tetracycline, 
bisphosphonates, peptide sequences, and various bone proteins 98. Tetracycline is a 
crystalline amphoteric substance that has the ability to bind to the surface of bone apatite 
crystals by chelation with surface calcium ions 98. These molecules bind strongly to bone 
mineral with minimal dissociation, but tetracycline has a poor chemical stability during 
modification. This instability eliminates the ability to conjugate drugs to the targeting 
molecule, making tetracycline an unusable targeting agent 98. In addition to their 
therapeutic effects, bisphosphonates have such a high affinity for bone they are also used 
as a targeting molecule to deliver other drugs. Bisphosphonates have been successfully 
conjugated to free drug 88, HPMA 90, 99-101, and PEG 98, 102 for controlled drug delivery. 
Bisphosphonates have also been altered to form a liposome to control the release of 
therapeutic agents from a scaffold material 94. The use of bisphosphonates allows for a 
cost effective and efficient method to target bone tissue, but these delivery vehicles must 
be specially designed to block the anti-resorptive effects of the bisphosphonate itself 98. 
Another common bone targeting agent is a D-aspartic acid octapeptide (Asp8) 90, 98-101. 
This peptide sequence can distinguish between functional domains of the skeleton and 
preferentially bind to resorptive sites 90, 98, 99. In recent studies targeting with Asp8 
resulted in longer circulation half-lives, preferential binding to eroded surfaces, and 
targeted biodistribution with over sixty percent of particles binding to the skeleton 90, 98-
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101. Polymalonic acid has also been under investigation for use in a targeted drug delivery 
system because it has a strong affinity to bind to hydroxyapatite. Though it has been 
successfully modified on the surface of drugs, no therapeutic effects have been reported 
98. Lastly, a few native bone proteins have been used as targeting agents for their ability 
to bind to available calcium ions. Osteocalcin and osteopontin are both negatively 
charged proteins that can bind to the positively charged calcium ions on the bone surface, 



















FORMULATION OF TARGETED HYDROXYAPATITE NANOPARTICLES FOR 




The goal of this research was to develop a hydroxyapatite nanoparticle targeted 
drug delivery system for the treatment of pathological loss of bone mineral density with 
statin therapies. In order to enhance biocompatibility and prolong systemic circulation 
time the hydroxyapatite particles were functionalization with poly(ethylene glycol) 
(PEG) with a poly(glycolic acid) (PGA) linker. The final formulation of the nanoparticles 
consists of a hydroxyapatite nanoparticle functionalized with a diblock copolymer of 
PGA-PEG, resulting in nHA-PGA-PEG. It has been proven that alterations in the ratio 
between components of polymeric diblock copolymers can alter the accumulation, 
biodistribution, and circulation time in vivo 102. For this reason, alterations were made in 
the formulation of these coated nanoparticles as a proof of concept that the polymer ratios 
can be changed such that an optimum ratio can be determined. After synthesis toxicity 
studies were completed on control, non-cancerous human umbilical vascular endothelial 
cells (HUVEC) to prove the particles non-toxic on their own.  
In order to develop a drug delivery system, the nanoparticle must be able to be 
loaded with the particular drug. The nHA-PGA-PEG particles were first loaded with a 
fluorescent dye and imaged to prove the ability to load the nanoparticles. Lovastatin, a 
common anabolic statin drug, was loaded into the nHA-PGA-PEG particles. A release 
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study was completed to determine the pharmacokinetics of the drug release from the 
newly formulated particles.  
Lastly, another goal was to use a targeting molecule on the surface of the 
nanoparticles to enhance delivery to bone tissue. Experiments were performed on various 
bone tissue samples followed by an in vitro study proving that the particular targeting 
peptide chosen in fact preferentially binds to calcium phosphate minerals. 
 
4.2. Materials 
 For the synthesis of nHA-PGA-PEG, nano-hydroxyapatite was purchased from 
SkySpring Nanomaterials. Also glycolide was bought from Sigma-Aldrich and methoxy-
poly(ethylene glycol)-isocyanate was from Nanocs, Inc. The anhydrous 
dimethylformamide and phosphazene base P2-t-Bu were also purchased from Sigma-
Aldrich. Lastly, molecular weight cutoff centrifugal filter units were purchased from 
Millipore. 
 Toxicity studies were completed using well plates from Corning, endothelial 
growth media purchased from Lonza, and Presto Blue Cell Viability Reagent from Life 
Technologies.  
In addition to the materials mentioned above, dye loading was completed with an 
Alexa Fluor 647 cadaverine from Life Technologies and acetonitrile purchased from 
Sigma-Aldrich. 
Additional materials utilized for the drug release studies include lovastatin 
purchased from TCI America. HyPure water was purchased from Fisher Scientific, 3.5 
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kC MINI Dialysis Units from Thermo Scientific, and methanol was from Sigma-Aldrich. 
The HPLC Alltima C18 column was purchased from Grace Davison. 
Lastly, peptide targeting studies were completed using peptides previously made 
in Dr. Alexis’s Nanomedicine Lab. The HA-1 fluorescent peptide had a peptide sequence 
of: Ser – Val – Ser – Val – Gly – Met – Lys – Pro – Ser – Pro – Arg – Pro – Gly – Gly – 
Gly – TAMARA and a molecular weight of 2124.38 grams/mole. The (Glu)8 fluorescent 
peptide has a sequence of: Glu – Glu – Glu – Glu – Glu – Glu – Glu – Glu – Gly – Gly – 
Gly – TAMARA and a molecular weight of 1892.75 grams/mole. 
 
4.3. Experiment Methods 
 
4.3.1. Synthesis of nHA-PGA-PEG 
In order to synthesize the nHA-PGA-PEG particles 40 milligrams of nano-
hydroxyapatite (nHA) and 464 milligrams of glycolide were weighed out and dried 
overnight under a 32 inches of mercury vacuum, in the same vial. Concurrently, 100 
milligrams of methoxy-poly(ethylene glycol)-isocyanate (mPEG-isc) was dried in a 
separate container, also overnight. The following day, the dried nHA and glycolide were 
dissolved in 3 milliliters of anhydrous dimethylformamide (DMF), and stirred for 30 
minutes at room temperature. Following stirring, 25 microliters of phosphazene base P2-t-
Bu solution was added. Both the reaction vessel and the dried mPEG-isc were purged 
with N2, and the reaction was stirred overnight. The next day, the dried mPEG-isc was 
dissolved in 1 milliliter of anhydrous DMF and added to the reaction vessel. The vial 
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containing the reactive components was purged under N2 and the reaction was stirred for 
an addition 24 hours. After the final stirring period, the contents of the reaction were 
washed twice in DMF using molecular weight cutoff (MWCO) centrifugal filter units at a 
speed of 5000 rpm for 5 minutes. After centrifuging, the supernatant was removed and 
the remaining pellet was re-dispersed before centrifuging again. Following both wash 
cycles, the samples were lyophilized for further analysis by thermogravimetric analysis 
(TGA) and Fourier transform infrared spectroscopy (FTIR).  
 
4.3.2. Toxicity 
HUVEC cells were seeded in 25 wells of a black, clear bottom, cell bind 96-well 
plate at a density of 10,000 cells/well in 200 microliters of endothelial growth cell media. 
Plates were then incubated overnight at 37C and 5% CO2 to allow the cells to adhere. The 
next day, 1 milligram of lyophilized nHA-PGA-PEG was weighed out. Solutions were 
made at concentrations of 0, 50, 100, 250, and 500 microgram nHA-PGA-PEG/milliliter 
cell media in a sterile hood. Then, 200 microliters of each nanoparticle concentration was 
added to each of 5 wells with HUVEC cells. The well plate was then incubated for 24 
hours at 37C and 5% CO2. After 24 hours, the cell media containing nanoparticles was 
removed and 200 microliters of fresh media was added to each well. The plates were then 
incubated at 37C and 5% CO2 for another 48 hours. After the final incubation, the cell 
media is removed and 100 microliters of a 10:1 solution of cell media to Presto Blue Cell 
Viability Reagent was added to each well. The well plate was then incubated at 37C and 
5% CO2 for 40 minutes covered from light. The fluorescence signal is then read using a 
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Biotek Synergy 4 fluorescent plate reader with Gen5 1.11 software with an excitation 
wavelength of 560 nanometers and an emission wavelength of 590 nanometers. The data 
is then analyzed by comparing the average fluorescent intensity of the samples with 0 
microgram/milliliter nanoparticle concentration as 100% viability to the average intensity 
of samples incubated with nanoparticles.  
 
4.3.3. Dye Loading 
In order to load a fluorescent dye, Alexa Fluor 647 (AF 647) cadaverine was 
dissolved at 1 milligram/milliliter in an 80:20 solution of DMF to acetonitrile (ACN). 
nHA-PGA-PEG particles were the dissolved at 1 milligram/milliliter in the AF 647-
DMF/ACN solution and stirred for 1 hour. The reaction solution was then dropped into 
water at a 1:2 nHA-PGA-PEG to water ratio and stirred for an additional 2 hours to 
evaporate the organic solvent. The nanoparticle solution was then washed twice in water 
with MWCO centrifugal filter units at 5000 rpm for 5 minutes. Again, after 
centrifugation the supernatant was removed and the remaining particles were resuspended 
in water before centrifuging again. Once washed, the nHA-PGA-PEG particles were re-
suspended in phosphate buffered saline (PBS) and imaged using the IVIS small animal 
imaging system located in the Godley-Snell Research Center. An excitation wavelength 
of 640 nanometers was used with a Cy.5.5 emission filter. Fluorescent imaging was used 
to detect the presence of AF 647 dye encapsulated within the nHA-PGA-PEG particle. 
 
4.3.4. Lovastatin Release 
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For the completion of the drug release study, 5 milligrams of lovastatin was 
dissolved in 1 milliliter of ACN. Then 1 milligram of nHA-PGA-PEG was weighed out 
and distributed evenly into five 1.5 milliliter microcentrifuge tubes. Then 200 microliters 
of lovastatin/ACN was added to each microcentrifuge tube, they were then wrapped in 
aluminum foil to protect them from light and rotated on a rotisserie for 1 hour. Next, 200 
microliters of the nHA-PGA-PEG-lovastatin/ACN solution was dropped into each of five 
vials containing 400 microliters of HyPure water. These solutions were then stirred for 2 
hours protected from light. The samples were then washed twice in water using MWCO 
centrifugal filter units as described previously. After washing, each sample was re-
dispersed in 200 microliters of water. 
The lovastatin-loaded nHA-PGA-PEG was added to the top of a 3.5 kD MINI 
Dialysis unit. The dialysis unit was then loaded into the top of a vial containing 7 
milliliters of HyPure water. Samples were placed in an incubator at 37C and 5% CO2. At 
each designated time point aliquots were taking from the bottom of the vial, and the 
sample was then lyophilized.  
High performance liquid chromatography (HPLC) was used to determine the 
amount of released lovastatin in each aliquot. The lyophilized samples were dissolved in 
1 milliliter of methanol, then filtered with a 0.2 micrometer nylon syringe filter and 
extruded into amber 2 milliliter HPLC vials. HPLC was then performed with a Waters 
1525 Binary HPLC pump with a 2998 photodiode array detector. An Alltima C18 column 
with 5 micrometer pores and dimensions of 250 x 4.6 millimeters was used. The mobile 
phase used was a 71% ACN, 29% 0.05 molar ammonium acetate at a pH of 4.0, titrated 
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with acetic acid. The flow rate of the HPLC system was set to 1 milliliter/minute and 
lovastatin was detected at a wavelength of 238 nanometers. Data is graphed at a 
cumulative release of lovastatin in micrograms over time as well as a percent cumulative 
release over time. 
 
4.3.5. Peptide Targeting 
A stock peptide-fluorescent molecule solution of 1 milligram/milliliter was 
diluted down to 0.2 milligram/milliliter in water. The peptide solution was then added to 
the deparafinized tissue array and/or the hydroxyapatite and chicken bone sample. 5.5 
microliters was added to the each sample on the tissue array and 50 microliters was added 
to the bone samples held within a clear non-sterile 96-well plate. The samples were then 
covered from light and incubated at room temperature for 2 hours to allow for peptide 
binding. After the incubation, the peptide solution was pipetted off the array sample 
and/or out of the well plate. The samples were then washed 3 times by pipetting water on 
and off the samples. The samples were then covered from light until imaging was done. 
Imaging was completed with the IVIS small animal imaging system at the Godley-Snell 
Research Center with an excitation wavelength of 535 nanometers and an emission filter 
of DSRed with a 1 second exposure. Data was analyzed by subtracting the fluorescent 
signal from blank samples, without peptide addition. In vivo studies were performed by 
injecting 1 milliliter of 0.2 milligram/milliliter fluorescent peptide solution intravenously 
according to approved animal protocols. Imaging was done 3 days after injection using 
the IVIS small animal imaging system with the same settings as mentioned above. 
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4.4. Experiment Results and Discussion 
 
4.4.1. Synthesis of nHA-PGA-PEG 
Synthesis of hydroxyapatite nanoparticles with a copolymeric coating of PGA-
PEG was successful, resulting in biocompatible particles for the use in drug delivery 
applications. Figure 4 shows the results of a TGA of the nHA nanoparticles with a PGA 
coating. Various monomer-to-catalyst ratios were used in order to alter the thickness of 
the PGA coating on the nHA particles. The various decaying profiles display that each 
ratio resulted in a different thickness coating. This experiment was used as a proof of 
concept that the thickness of the PGA coating can be controlled during synthesis. This 
control is important because the size and molecular weight of particles can greatly affect 
the circulation time, biodistribution, and accumulation of particles 98. With the ability to 
control the coating thickness, an optimum thickness, and therefore molecular weight, of 
the nanoparticles can be determined. After successful functionalization of PGA on the 
nanoparticle surface, PEGylation was done in order to increase biocompatibility and 
circulation time. Figure 5 shows a TGA of just nHA, nHA-PGA, and nHA-PGA-
PEGmal. The different decomposition temperatures of each sample prove that PEG was 
conjugated to the PGA. The PEG used in this formulation had a maleimide functional 
group; this end group was needed such that a targeting molecule can be further added to 





















































Figure 4 | Successful Variation of PGA Coating Thickness. Various monomer to 
catalyst ratios were used to prove polymeric coating thickness can be controlled. 
Figure 5 | Conjugation of PEG to nHA-PGA. PEGylation of nHA-PGA particles 
is successful, evident by the difference in decomposition temperature. 
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After successful synthesis of nHA particles with a PGA-PEG coating, TEM 
images were taken in order to view the size change due to the polymer coating. The 
image of the left in Figure 6 is a TEM of just nHA, as shown these structures have a 
much smaller diameter. The image on the right is of nHA-PGA-PEG particles. The 
thickness change is evident indicated a successful conjugation of PGA-PEG on the 
surface of the nHA particles. 
 
4.4.2. Toxicity 
Toxicity studies were performed to determine the interaction these nHA-PGA-
PEG particles would have with a normal cell. HUVEC cells were used as a control for a 
noncancerous cell. These studies showed that these particles showed a slight, but not 
Figure 6 | TEM Images of (Left) nHA and (Right) nHA-PGA-PEG. PGA-PEG 
coating was evident by transmission electron microscopy by the variation in size 
from the non-coated particles. 
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detrimental toxicity in cells. The viability remained around 80% even at higher 
nanoparticle concentrations such as 500 micrograms/milliliter. For the purposes of this 




4.4.3. Dye Loading 
Upon successful formulation of nHA-PGA-PEG nanoparticles, it must be shown 
that these particles can be loaded with substance for eventual release. A fluorescent dye 
was used as a proof of concept that these particles can be loaded. The image below shows 
a solution of dispersed nHA-PGA-PEG particles loaded with fluorescent dye. As 
compared to the solution of non-loaded nHA-PGA-PEG, the fluorescent signal is much 
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Figure 7 | Toxicity of nHA and nHA-PGA-PEG in HUVEC Cells. Cell viability 
around 80% for elevated nanoparticle concentration indicates an acceptable toxicity. 
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the right is a chart comparing the actual fluorescent signal intensities, as shown the 





4.4.4. Lovastatin Release 
The next step in the formulation of nHA-PGA-PEG nanoparticles for drug 
delivery was to load these particles with a desired therapy and monitor the 
pharmacokinetics of the release. An HPLC release study was conducted to determine the 
release profile of the newly formulated nHA-PGA-PEG nanoparticles. Figure 9 shows the 
cumulative release of lovastatin over a two-week time period. It was shown that the 
lovastatin was released linearly over time, with the entire drug reservoir being released 






















  Control           Dye-loaded 
Figure 8 | Dye Loading Used as Proof of Concept for Nanoparticle Loading 
Abilities. Successful loading of a fluorescent dye proves the ability of the 
formulated nHA-PGA-PEG nanoparticles to be loaded with drug. 
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The varying thickness resulted in different release profiles, proving that the release of 






4.4.5. Peptide Targeting 
The final goal of this research was the use of a targeting molecule on the surface 
of the particles to enhance of the specificity of the delivery to bone tissue. A peptide 
solution was used as a proof of concept that these peptides can bind to bone and will do 
Figure 9 | Lovastatin Release from nHA-PGA-PEG Nanoparticles. HPLC 
release study showed that nHA-PGA-PEG release kinetics can be controlled with 
variations in PGA coating. G200-PEG is 20 wt% PGA, G100-PEG is 40 wt% PGA, 
and G50-PEG is 60 wt% PGA. 
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so preferentially. Experiments were first conducted using hydroxyapatite disks and 
samples of decellularized chicken bone to prove the ability of the peptide to bind to the 
bone surface. The binding abilities were then tested in vivo with a mouse model, the 
images on the right of Figure 11 show that even within the physiological environment 
these two peptides were able to bind to the bone surface. Though both peptides have 
binding abilities the HA-1 peptide had a stronger fluorescent signal. Moving forward the 
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Figure 10 | Targeting Peptide Binding to HA Discs and Chicken Bone. Binding 
abilities of bone-targeting peptides were tested using hydroxyapatite discs and 









It is necessary for a targeting molecule to not only bind to the preferred tissue, but 
it must do so preferentially. An array of human tissue samples was used in order to 
determine the specificity of the HA-1 peptide. Figure 12 shows that the peptide binding 
to bone tissue was much higher than that of any other tissue. Proving the specificity of 
the HA-1 peptide was sufficient to provide a targeted delivery. This experiment also 
proved that this peptide does not have a tendency to accumulate in tissues such as the 
heart, lungs, or brain where the accumulation of unwanted particles could result in 
serious side effects.  
 
Figure 11 | In Vivo Testing of Bone-
Targeting Peptide Binding. In vivo 
experiments were performed to determine the 










4.5. Conclusion of Results 
 The synthesis of nHA-PGA-PEG nanoparticles able to encapsulate and deliver 
drugs with controlled pharmacokinetics was achieved. Not only was a polymeric surface 
coating conjugation demonstrated, but also the thickness of the PGA can be controlled. 
This controllable thickness directly correlates to an ability to control the release profile of 
the nanoparticles, as shown with the variation in release profiles determined by an HPLC 
release study of lovastatin. The next step in the fabrication of these nanoparticles is the 
development of a targeting mechanism to prevent the delivery of statin drugs to other 
tissues in the body. Two peptides, made by members of the nanomedicine lab, were 
Figure 12 | Preferential Binding of HA-1 Peptide to Bone Tissue. A human tissue 
array was used to determine the specificity of HA-1 binding to bone tissue. 
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tested for their efficacy and specificity of bone targeting. The HA-1 peptide demonstrated 
both in vitro and in vivo targeting abilities for the calcium phosphate mineral component 
of bone tissue. These were assessed using hydroxyapatite discs and decellularized 
samples of chicken bone as well as an in vivo study with the peptide solution injected 
intravenously. The in vivo images not only show that these peptides can bind in the 
physiological environment, but because these images were taken three days after 
injection, they also prove the peptides remain bound to the surface. These particles show 







 The high prevalence of osteoporosis, as well as the deformity and pain of Paget’s 
and microgravity bone loss, is evidence that effective treatments are of a highest priority. 
Presently, there are many treatment options that can prevent further bone loss and even 
increase the bone mineral density slightly. More focus must be placed on anabolic 
treatments to allow the recovery and rehabilitation of lost tissue. Statins have promising 
results for the induction of bone formation by the increase in BMP-2 mRNA. With these 
nHA-PGA-PEG nanoparticles, these statin molecules could be delivered directly to the 
skeleton to allow for a quick and efficient increase in the natural formation process. 
These particles have proven abilities to be loaded with drug and release that loaded drug 
with a controllable profile. Hydroxyapatite particles are known to target bone due to the 
chemical likeness of the molecules, but to enhance the targeting, peptide sequences have 
been tested for binding efficiency and specificity. It is shown that both peptides tested 
can exclusively target bone and remain bound to the surface.  
 This research has many implications for potential drug delivery applications. The 
use of a hydroxyapatite core provides a particle with minimal immune response; then the 
addition of a polymeric coating enhances the biocompatibility and circulation time within 
the body. These developed nanoparticles provide an ability to controllably deliver 
lovastatin to increase bone formation with a targeting mechanism that allows these 
anabolic bone agents to be delivered to bone with both efficiency and specificity. 
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 In all, these particles show promise for future development as a potential targeted 










RECOMMENDATIONS FOR FUTURE RESEARCH 
 
 
1. Conjugation of HA-1 peptide to the maleimide group at the end of the PEG 
segment of the polymeric PGA-PEG surface coating. 
a. Conjugation has been successful but the process must be optimized to 
provide both consistent and reproducible peptide conjugation. 
2. Targeting and non-targeting uptake into osteoblast and control, HUVEC, cells. 
a. The goal of this experiment is to prove the efficacy of the targeting 
approach. The uptake of targeted particles in to cells should be higher than 
that of untargeted particles. 
3. In vivo animal studies of HA-1 targeted nHA-PGA-PEG particles. 
a. These animal studies will be used to prove that the targeted nanoparticles 
predominantly accumulate in the bone, while also having minimal 
accumulation in the other tissues such as the heart, brain, and lungs where 
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